Cancer Home > Generic Aranesp
At this time, there are no generic Aranesp products available. Since Aranesp is a "biologic" medication, it is under a specific set of rules and laws that prevents any generic versions from being manufactured. Until these laws are changed in the future, drug companies may never be allowed to produce generic Aranesp.
Aranesp® (darbepoetin alfa) is a prescription medication used to treat anemia. It is approved to treat anemia caused by chronic kidney failure (renal failure) or chemotherapy.
Aranesp is made by Amgen, Inc. Technically, Aranesp is considered to be a "biologic" medication. Biologic medications are under different rules and laws than most other medications. At this point, generic biologics, including generic Aranesp, are not allowed to be made.
Biologics are products that are made using live cells or organisms. The cells or organisms are used to produce certain complex proteins or molecules that are used as medications, and the medications are known as "biologics" or "biopharmaceuticals." Aranesp is considered a biologic medication because it is a man-made version of a human protein and is produced using hamster ovary cells.
When the patents for regular drugs expire, generic companies can apply to make generic versions. These companies need to submit a little information proving that their product is the same as the brand-name version, but they do not have to repeat all of the human studies to show the drug to be safe and effective. Human studies are very expensive and time consuming, and generic medications are less expensive because they do not need all the human studies.
However, biologics are governed by a different set of laws. Currently, there is no way for a generic biologic to be approved under these laws, unless the generic manufacturer completes all of the human studies necessary to approve a brand-new drug. Because such studies are extremely expensive, it is likely that a generic biologic would not be any less expensive than the brand-name product. Essentially, if a generic biologic were to be approved, it would not really be a generic, but a new and separate drug (that would not be equivalent to the brand-name product).
Recently, there has been much interest in changing these laws, and it is likely that generic biologics will be allowed in the near future.